DrugPatentWatch Database Preview
Drugs in Development Information for Alisertib
Email this page to a colleague
» See Plans and PricingWhat is the development status for investigational drug Alisertib?
Alisertib is an investigational drug.
There have been 47 clinical trials for Alisertib.
The most recent clinical trial was a Phase 2 trial, which was initiated on January 1st 2018.
The most common disease conditions in clinical trials are Lymphoma, Neoplasms, and Adenocarcinoma. The leading clinical trial sponsors are Millennium Pharmaceuticals, Inc., National Cancer Institute (NCI), and Takeda.
There are seventeen US patents protecting this investigational drug and two hundred and twenty international patents.
Summary for Alisertib
| US Patents | 17 |
| International Patents | 220 |
| US Patent Applications | 41 |
| WIPO Patent Applications | 20 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2018-01-01) |
| Vendors | 71 |
Recent Clinical Trials for Alisertib
| Title | Sponsor | Phase |
|---|---|---|
| Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer | Takeda | Phase 1 |
| Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer | Collin Blakely | Phase 1 |
| Romidepsin Versus Combination of Romidepsin Plus Pralatrexate in PTCL | Columbia University | Phase 3 |
Clinical Trial Summary for Alisertib
Top disease conditions for Alisertib
Top clinical trial sponsors for Alisertib
US Patents for Alisertib
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Alisertib | Start Trial | Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido [5,4-D][2]benzazepin-2-YL]amino}-2-methoxybenzoate | Millennium Pharmaceuticals, Inc. (Cambridge, MA) | Start Trial |
| Alisertib | Start Trial | Combinations of LSD1 inhibitors for use in the treatment of solid tumors | Oryzon Genomics, S.A. (Madrid, ES) | Start Trial |
| Alisertib | Start Trial | Combination of aurora kinase inhibitors and anti-CD30 antibodies | Millennium Pharmaceuticals, Inc. (Cambridge, MA) | Start Trial |
| Alisertib | Start Trial | Combination of aurora kinase inhibitors and anti-CD20 antibodies | Millennium Pharmaceuticals, Inc. (Cambridge, MA) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Alisertib
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Alisertib | Brazil | 112012020557 | 2030-02-19 | Start Trial |
| Alisertib | Canada | 2788774 | 2030-02-19 | Start Trial |
| Alisertib | China | 102770024 | 2030-02-19 | Start Trial |
| Alisertib | China | 104031049 | 2030-02-19 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
